Onconetix (ONCO) Accumulated Expenses (2021 - 2026)
Onconetix (ONCO) posted quarterly Accumulated Expenses of $1704.0 for Q1 2026, down 99.31% year-over-year from $245716.0 in Q1 2025, and down 99.5% quarter-over-quarter from $341881.0 in Q4 2025.
Onconetix (ONCO) Accumulated Expenses (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Accumulated Expenses for 6 consecutive years, with $1704.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 99.31% year-over-year to $1704.0; the TTM figure through Mar 2026 stood at $1704.0 (down 99.31% YoY), while the FY2025 annual figure was $341881.0, up 145.24% from the prior year.
- Accumulated Expenses slipped to $1704.0 in Q1 2026 per ONCO's latest filing, from $341881.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.6 million in Q3 2022 and bottomed at $879.0 in Q3 2025.
- Historically, Accumulated Expenses has averaged $890600.6 across 5 years, with a median of $341881.0 in 2025.
- Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 1426.46% — and 2025, when it slumped 99.66%.
- Onconetix's Accumulated Expenses stood at $2.4 million in 2022, then plunged by 97.92% to $50000.0 in 2023, then jumped by 178.82% to $139409.0 in 2024, then soared by 145.24% to $341881.0 in 2025, then sank by 99.5% to $1704.0 in 2026.
- Business Quant data shows ONCO's Accumulated Expenses at $1704.0 in Q1 2026, $341881.0 in Q4 2025, and $879.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249,607.00 |
| Mar 31, 2026 | 1,704.00 |
| Dec 31, 2025 | 341,881.00 |
| Sep 30, 2025 | 879.00 |
| Jun 30, 2025 | 396,091.00 |
| Mar 31, 2025 | 245,716.00 |
| Dec 31, 2024 | 139,409.00 |
| Sep 30, 2024 | 255,679.00 |
| Jun 30, 2024 | 206,722.00 |
| Mar 31, 2024 | 568,559.00 |
| Dec 31, 2023 | 50,000.00 |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 37,247.00 |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 3.56 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 1.06 Mn |